SAN
JOSE, Calif., Dec. 19,
2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:
ANIX), a biotechnology company focused on the treatment and
prevention of cancer and infectious diseases, today
announced that it will present at the Biotech Showcase 2023
conference being held in-person on January
9-11, 2023, at the Hilton San Francisco Union Square in
San Francisco, California, and
virtually on January 18-19,
2023.
The presentation will provide an overview of Anixa's business
and highlight recent corporate achievements, including updates on
its clinical programs.
Details of the presentation are as follows:
Event:
Biotech Showcase 2023
Date:
Monday, January 9,
2023
Time:
3:30 PM
PST
Location:
Yosemite-A, Hilton San Francisco Union Square
Anixa management will be available for one-on-one meetings
throughout the conference.
Biotech Showcase is one of the industry's largest annual
healthcare investor and partnering conferences, bringing together
biopharmaceutical and life sciences company executives, investors,
sector analysts, bankers, and industry stakeholders. More
than 350 presentations from mid-, small- and micro-cap public and
private companies are expected to present at the event.
Qualified investors and buy- and sell-side analysts are invited to
request a complimentary registration to attend Biotech
Showcase. For more information on attending
click here.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company with programs addressing
cancer and infectious disease. Anixa's portfolio
of therapeutics includes a cancer immunotherapy
program being developed in collaboration with Moffitt
Cancer Center, which uses a novel type of CAR-T,
known as chimeric endocrine receptor T-cell
(CER-T) technology, and, with partner
MolGenie GmbH, a COVID-19 program focused on compounds
targeting the Mpro enzyme of SARS-CoV-2,
which is largely conserved across all recently identified
variants. The company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple negative breast cancer
(TNBC), the most lethal form of the disease – as well
as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of
cancer. Anixa's unique business model of
partnering with world-renowned research institutions on clinical
development allows the company to continually examine emerging
technologies in complementary fields for further development and
commercialization. To learn more, visit www.anixa.com
or follow Anixa on Twitter,
LinkedIn, Facebook and
YouTube.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented in this press release.
Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-biotech-showcase-2023-301705631.html
SOURCE Anixa Biosciences, Inc.